Deciphera Pharmaceuticals - DCPH Stock Forecast, Price & News

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DCPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DCPH, but not buy additional shares or sell existing shares.
View DCPH analyst ratings or view top-rated stocks.

11 equities research analysts have issued 12-month target prices for Deciphera Pharmaceuticals' shares. Their DCPH share price forecasts range from $6.00 to $25.00. On average, they anticipate the company's share price to reach $19.44 in the next twelve months. This suggests a possible upside of 5.2% from the stock's current price.
View analysts price targets for DCPH or view top-rated stocks among Wall Street analysts.

Deciphera Pharmaceuticals' stock was trading at $9.77 at the beginning of 2022. Since then, DCPH stock has increased by 89.2% and is now trading at $18.48.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our DCPH earnings forecast.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) issued its quarterly earnings data on Thursday, August, 4th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.05. The business had revenue of $32.49 million for the quarter, compared to analysts' expectations of $30.11 million. Deciphera Pharmaceuticals had a negative net margin of 231.99% and a negative trailing twelve-month return on equity of 74.37%. The firm's revenue for the quarter was up 37.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.21) EPS.

3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

(DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DCPH stock can currently be purchased for approximately $18.48.

Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $1.23 billion and generates $96.15 million in revenue each year. The company earns $-299,960,000.00 in net income (profit) each year or ($4.28) on an earnings per share basis.

The company employs 280 workers across the globe.

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for the company is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at eciphera@argotpartners.com.